Publication: 3000

Publication: 3000

RATIFY: Prognostic impact of FLT3 tyrosine kinase domain (TKD) and NPM1 mutation status in patients with newly diagnosed acute myeloid leukemia (AML) treated with midostaurin or placebo plus standard chemotherapy (Alliance)

DOI

URL

Google Scholar

Citation:: Blood vol 132 (Suppl 1) 2668

Meeting Instance:: ASH 2018
Year:: 2018
Type:: Abstract
Sub type:: Poster Discussion
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epreprint

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3327 3235

Program:: OGC
Primary Committee:: Leukemia
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, U10CA180820, U10CA180791, U10CA180888, U10CA180863, (CCSRI) #704970, U24CA196171

Corr. Author:
Authors:: Maria Teresa Voso Richard A. Larson Thomas W Prior Guido Marcucci Dan Jones Jürgen Krauter Michael Heuser Serena Lavorgna Josep Noedeu Kristine Laumann Susan M. Geyer Rebecca B. Klisovic Andrew Wei Jorge Sierra Miguel A. Sanz Joseph M. Brandwein T. M. M de Witte Joop H. Jansen Dietger Niederwieser Frederick R. Appelbaum Bruno C. Medeiros Martin S. Tallman Richard F. Schlenk Arnold Ganser Hubert Serve Gerhard Ehninger Sergio Amadori Yuan Cheng Insa Gathmann Eva Tiecke Christian Thiede Konstanze Döhner Hartmut Döhner Richard M. Stone Clara D. Bloomfield Francesco Lo-Coco

Networks:: CA043, LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-OH007, LAPS-WI013

Study: CALGB-10603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: